Hepatocellular Carcinoma Recurrence in a Patient with Impaired Renal Function
Rika Iwamasa, MD*; Kenji Shinozaki, MD*; Tetsuya Minamide** | 02.04.2018
* Department of Diagnostic Imaging and Nuclear Medicine, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan
** Department of Radiology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan
A 97-year-old male patient suffering from hepatocellular carcinoma (HCC) underwent multiple sessions of transcatheter arterial chemoembolization (TACE) within the past 7 years. He was referred for an assessment of a HCC recurrence due to an elevated alphafetoprotein (AFP) serum level. Regularly, it would require 600 mgI/kg for the diagnosis of HCC in our institution. Taking into consideration his impaired kidney function (eGFR 32 mL/min/1.73 m2), only 300 mgI/kg was administrated. A TwinBeam Dual Energy (TBDE) CT was performed.
The outcomes by Siemens Healthineers customers described herein are based on results that were achieved in the customer’s unique setting. Since there is no “typical” hospital and many variables exist (e.g., hospital size, case mix, level of IT adoption) there can be no guarantee that other customers will achieve the same results.